Overview

NCI Definition [1]:
An orally bioavailable oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration of the OxPhos inhibitor IACS-010759, this agent binds to and inhibits complex I of the electron transport chain (NADH ubiquinone oxidoreductase), thereby selectively depriving tumor cells of nutrients, and energy, and inhibiting nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation. Mitochondrial complex I, which is hyperactivated in cancer cells to meet their increased demands for energy, plays a key role in the promotion of cancer cell proliferation.

Iacs-010759 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating iacs-010759, 2 are phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for iacs-010759 clinical trials.

Breast carcinoma, lymphoma, and malignant solid tumor are the most common diseases being investigated in iacs-010759 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Iacs-010759
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Iacs-010759
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating iacs-010759 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
oxphos inhibitor iacs-010759, oxidative phosphorylation inhibitor iacs-010759
Drug Target(s) [2]:
NDUFA1, NDUFB10, NDUFB2, NDUFB7, NDUFB8, NDUFS1
NCIT ID [1]:
C130012

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.